Breast Cancer
Conditions
Keywords
HER2-positive, early breast cancer
Brief summary
Open-label, multicenter phase I/II trial. Patients with HER2-positive (overexpressing or amplified), invasive breast cancer with T1c N1-2 or T2 N0-2 disease will be treated with * Non-pegylated liposomal doxorubicin (NPLD; Myocet, 60 mg/m\^2 i.v. day 1 q3 weeks), * Paclitaxel (175 mg/m\^2 i.v. day 1 q3 weeks), and * Lapatinib (GW572016, Tykerb, 750-1500 mg/d orally daily until the day of the definitive surgery) Treatment is planned for 6 cycles unless there is evidence of unacceptable toxicity, disease progression or inadequate efficacy (defined as a decrease in tumor size \<25% after 4 courses measured by ultrasound or MR-mammography), or if the patient requested to be released.
Detailed description
Breast cancer is the most common malignancy affecting females in northern Europe and North America, corresponding to an age-corrected annual incidence of 100 to 120 per 100000 females. Approximately 30-40% of all patients treated with curative intent will develop metastatic disease. Perioperative systemic treatment has made a major impact on relapse-free and overall survival of women with early-stage breast cancer \[ , \] with therapeutic strategies being based on the endocrine responsiveness and the estimated risk of relapse defined by tumor size, axillary lymph node involvement, histologic and nuclear grade, lymphatic and/or vascular invasion, HER2/neu-overexpression and age \[ \]. Perioperative therapy has traditionally been administered postoperatively, but chemotherapy is increasingly utilized in the preoperative setting as it can significantly improve the rate of breast conserving surgery, and new regimens can be evaluated rapidly and more precisely.
Interventions
DRUGMyocet (Non-pegylated liposomal doxorubicin (NPLD))
60 mg/m\^2 i.v. day 1 q3 weeks
DRUGPaclitaxel
175 mg/m\^2 i.v. day 1 q3 weeks
DRUGLapatinib (GW572016, Tykerb)
750-1500 mg/d orally daily until the day of the definitive surgery
Sponsors
Prof Dirk Elling
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically confirmed breast cancer * T1c N1-2 or T2 N0-2 disease * HER2-positive tumours with 3+ intensity on immunohistochemical staining for HER2 or amplification of the HER2 gene on fluorescence in situ hybridization (FISH) * No prior systemic treatment regimens for breast cancer * Adequate hematologic function (ANC 1500 cells/µl, platelet count 100000/µl, and hemoglobin 8g/dl). * Serum creatinine concentration \< 1.5 times the upper limit of normal (ULN) and/or creatinine clearance \>60 ml/min * Bilirubin level \< 1.5 X ULN * Normal cardiac function with a left ventricular ejection fraction of at least 50% (as assessed by quantitative echocardiogram or MUGA scan) * Karnofsky performance status 80% * Age 18 years * If the patient is of childbearing potential, she agrees to: comply with effective contraceptive measures, has been using adequate contraception since the last menses, will use adequate contraception during the study, and has a negative pregnancy test within one week of study entry * Written informed consent prior to admission to this study
Exclusion criteria
* Male patients * Inflammatory or bilateral breast cancer * Evidence of distant metastases * Previous systemic or local treatment for breast cancer (including surgery, radiotherapy, cytotoxic and endocrine treatments) * Past or current history of other neoplasms, except for * Curatively treated non-melanoma skin cancer * Adequately treated in situ carcinoma of the cervix * Other cancer curatively treated and with no evidence of disease for at least 5 years * Significant cardiac disease, including angina pectoris, severe cardiac arrhythmia requiring medication, severe conduction abnormalities, clinically significant valvular disease, cardiomegaly, ventricular hypertrophy, poorly uncontrolled hypertension (resting diastolic blood pressure \>115 mmHg), prior myocardial infarction, CHF, or other cardiomyopathy * Preexisting sensoric or motor polyneuropathy Grade 2 according to NCI CTC * Serious intercurrent medical or psychiatric illness, including serious active infection * Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational drug within 30 days prior to study entry. * Detained persons or prisoners * Pregnant or nursing women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determine the optimal doses for NPLD, paclitaxel and lapatinib (phase I) | every 3 weeks |
| Evaluate the pathological response to NPLD, paclitaxel and lapatinib (phase II) | every 6 weeks |
Countries
Germany
Outcome results
None listed